Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Generic drugs in Spain: first stage].

M Siles Gutiérrez1, M Goldaracena Tanco

  • 1Dirección Territorial INSALUD, Inspección Farmacéutica, Zaragoza. msiles@dtz.insalud.es

Atencion Primaria
|September 21, 2000
PubMed
Summary

Generic medicine consumption in Spain is growing but has not reached its full potential, resulting in substantial unachieved savings. The supply of these cost-effective alternatives is also steadily increasing.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Use of hypolipemic agents in Spain, 1987-2000].

Revista espanola de salud publica·2001
Same author

[Potential impact of measures to minimize drug costs in Aragon's primary care system].

Atencion primaria·1999
Same author

[The utilization of anti-infective agents in primary care in La Rioja].

Atencion primaria·1999
Same author

[Extra-hospital consumption of anti-infective agents in a defined daily doses per thousand inhabitants per day].

Atencion primaria·1996

Area of Science:

  • Pharmacoeconomics
  • Pharmaceutical policy

Context:

  • Observational, retrospective study analyzing the Spanish National Health System.
  • Data from medical prescriptions issued between October 1997 and December 1998.

Purpose:

  • To analyze the consumption patterns and supply of generic medicines.
  • To quantify potential savings achievable through increased generic medicine utilization.

Summary:

  • Total consumption of generic medicines reached 10.4 million euros (0.15% of total pharmaceutical spending).
  • Potential additional savings were estimated at 79.5 million euros.
  • The number of available generic medicines increased to 67 by May 1999.

Impact:

  • Despite steady growth, generic medicine uptake remains below its potential, indicating significant opportunities for cost savings.
  • The study highlights the need for policies to maximize generic medicine utilization within the National Health System.

Related Experiment Videos